SecBot SecBot
Insider Cluster (2 insiders) ·Filed Nov 12, 2026

BIO

BIO-RAD LABORATORIES, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed4d 16h ago
Insider cluster: 2 insiders, $899K total
Actionable Insight • Neutral

The sales are very small relative to market cap and follow a positive earnings report, making them likely routine portfolio adjustments. Monitor for any larger insider selling or changes in forward guidance that could signal a shift in management's outlook.

DirectionNeutral
Confidencemedium
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$370.48
T+0 close · Nov 12, 2026 · via day close
Latest settled
−1.11%
T+1 · $366.36
Vs SPY
−0.75%
α at T+1
Next horizon
T+5
in 2d
  1. T+0 · Nov 12 $370.48entry
  2. T+1 · 4d ago −1.11%α −0.75% · $366.36
  3. T+2 · todayOpen
  4. T+5 · in 2d Pending
  5. T+20 · in 24d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two senior executives at Bio-Rad (President & COO and EVP/President of Life Science Group) sold a combined $899K in open-market shares on November 9, 2026, eight days after the company reported a Q3 earnings beat with revenue slightly above consensus but maintained guidance for a potential full-year revenue decline. The sales are not under 10b5-1 plans and follow the earnings release, suggesting possible profit-taking or portfolio rebalancing after the positive results.

Key Financial Metrics

Direction
selling
Total Value
$898.7K
Insiders
2

Key Facts

  • President & COO Jonathan DiVincenzo sold 919 shares at $390.47 for $359K on Nov 9, 2026
  • EVP/President LSG James Barry sold 1,400 shares at $385.63 for $540K on Nov 9, 2026
  • Total open-market sales of $899K represent ~0.009% of Bio-Rad's $10.4B market cap
  • Neither sale was executed under a 10b5-1 plan
  • Sales occurred 8 days after Q3 2026 earnings beat (non-GAAP EPS $2.65 vs $2.23 consensus)

Financial Impact

Total insider sales of $899K, negligible relative to $10.4B market cap

Risk Factors

  • Sales by two senior executives on the same day could indicate coordinated profit-taking
  • No 10b5-1 plan provides a pre-planned defense for the timing

Market Snapshot

Exchange
NYSE
Sector
Laboratory Analytical Instruments
Analyst Consensus
50% bullish (10 analysts)

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-BIO-1794499138165

US Market Status

Market Closed · Opens in 6h 4m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026